Figure 1: Western blot analysis using GSK3B mouse mAb against A549 (1), K562 (2), PC-12 (3), NIH/3T3 (4), and HEK293 (5) cell lysate.
Mouse Monoclonal Antibody to GSK3B

Mouse Monoclonal Antibody to GSK3B


Regular price $308.00 $262.00 You Pay

Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: Glycogen synthase kinase 3 (GSK-3), a serine-threonine kinase with two isoforms (alpha and beta), was originally discovered as a key enzyme in glycogen metabolism. GSK-3 was subsequently shown to function in cell division, proliferation, motility and survival. GSK-3 plays a role in a number of pathological conditions including cancer and diabetes and is increasingly seen as an important component of neurological diseases. GSK-3 phosphorylates tau and presenilin-1, which are involved in the development of Alzheimer's disease. Both isoforms of GSK-3 are ubiquitously expressed, although particularly high levels of GSK-3beta are found in the brain where it is involved in synaptic plasticity, possibly via regulation of NMDA receptor trafficking. GSK-3 phosphorylates over 40 different substrates including signaling proteins, transcription factors and structural proteins, and is part of the signal transduction cascade of a large number of growth factors and cytokines. The activity of GSK is regulated by phosphorylation (Akt: Akt-mediated phosphorylation at Ser21 of GSK-3? and Ser9 of GSK-3?, S6K, RSK, PKA and PKC), dephosphorylation (PP1 and PP2A), and by binding to protein complexes (with beta-catenin, axin, CK1 and the APC complex).
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000; ICC: 1/200 - 1/1000; FCM: 1/200 - 1/400
Size: 100 ul, 1mg/ml
Species Reactivity: Human; Mouse; Monkey; Rat
Clone: 3D10;
Isotype: Mouse IgG2a
Immunogen: Purified recombinant fragment of human GSK3B expressed in E. Coli.;
Formulation: Ascitic fluid containing 0.03% sodium azide.
MW: 46kDa
Storage: 4C; -20C for long term storage
Spplier link:
Reference: 1. EMBO J. 1998 Mar 2;17(5):1371-84. ; ; 2. Curr Biol. 2001 Jan 9;11(1):44-9. ; ; 3. Cancer Lett. 2003 Sep 25;199(2):201-8.